Clinical trial
Safety Study of an Immune Response Modifier in Patients With Refractory Solid…
NCT00095160 · Masonic Cancer Center, University of Minnesota, Other · Completed
Key facts
| NCT number | NCT00095160 |
|---|---|
| Title | Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors |
| Official title | Phase I, Open Label Safety, Pharmacokinetic, and Pharmacodynamic Dose Escalation/De-escalation Study of 852A Administered Intravenously to Subjects With Refractory Solid Organ Tumors |
| Lead sponsor | Masonic Cancer Center, University of Minnesota, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | 852A |
| Enrollment | 42 |
| Start date | Oct 1, 2003 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Nov 2, 2004 |
| Last update posted | Nov 29, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: